The FDA approved oral iptacopan (Fabhalta; Novartis) to reduce proteinuria in adults with C3 glomerulopathy (C3G), according ...

Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen ...